How to buy Penumbra stock | $278.19

Penumbra Inc is a medical devices business based in the US. Penumbra shares (PEN) are listed on the NYSE and all prices are listed in US Dollars. Penumbra employs 3,300 staff and has a trailing 12-month revenue of around 0.00.

Penumbra stock price (NYSE: PEN)

Use our graph to track the performance of PEN stocks over time.

Penumbra shares at a glance

• Key figures

Information last updated 2021-10-24.

Latest market close	$278.19
52-week range	$163.49 - $315.00
50-day moving average	$271.75
200-day moving average	$270.08
Wall St. target price	$324.83
PE ratio	648.8372
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.43

Buy Penumbra shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Penumbra stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Penumbra price performance over time

Historical closes compared with the close of $278.19 from 2021-10-25

1 week (2021-10-18)	4.68%
1 month (2021-09-23)	-1.56%
3 months (2021-07-27)	6.49%
6 months (2021-04-27)	-8.08%

1 year (2020-10-27)	16.48%
2 years (2019-10-25)	76.39%
3 years (2018-10-26)	101.66%
5 years (2016-10-27)	330.63%

Is Penumbra under- or over-valued?

Valuing Penumbra stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Penumbra's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Penumbra's P/E ratio

Penumbra's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 649x. In other words, Penumbra shares trade at around 649x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Penumbra's EBITDA

Penumbra's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $33.1 million.

The EBITDA is a measure of a Penumbra's overall financial performance and is widely used to measure a its profitability.

Penumbra financials

Revenue TTM	$671.4 million
Operating margin TTM	3.02%
Gross profit TTM	$356.6 million
Return on assets TTM	1.5%
Return on equity TTM	1.85%
Profit margin	2.37%
Book value	$18.57
Market capitalisation	$10.4 billion

TTM: trailing 12 months

Shorting Penumbra shares

There are currently 1.7 million Penumbra shares held short by investors – that's known as Penumbra's "short interest". This figure is 4.8% up from 1.7 million last month.

There are a few different ways that this level of interest in shorting Penumbra shares can be evaluated.

Penumbra's "short interest ratio" (SIR)

Penumbra's "short interest ratio" (SIR) is the quantity of Penumbra shares currently shorted divided by the average quantity of Penumbra shares traded daily (recently around 181625.96858639). Penumbra's SIR currently stands at 9.55. In other words for every 100,000 Penumbra shares traded daily on the market, roughly 9550 shares are currently held short.

However Penumbra's short interest can also be evaluated against the total number of Penumbra shares, or, against the total number of tradable Penumbra shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Penumbra's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Penumbra shares in existence, roughly 50 shares are currently held short) or 0.0596% of the tradable shares (for every 100,000 tradable Penumbra shares, roughly 60 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Penumbra.

Find out more about how you can short Penumbra stock.

Penumbra share dividends

We're not expecting Penumbra to pay a dividend over the next 12 months.

Have Penumbra's shares ever split?

Penumbra's shares were split on a 10:1 basis on 15 November 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Penumbra shares – just the quantity. However, indirectly, the new 90% lower share price could have impacted the market appetite for Penumbra shares which in turn could have impacted Penumbra's share price.

Penumbra share price volatility

Over the last 12 months, Penumbra's shares have ranged in value from as little as $163.49 up to $315. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Penumbra's is 0.3159. This would suggest that Penumbra's shares are less volatile than average (for this exchange).

Penumbra overview

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc.

Frequently asked questions

What percentage of Penumbra is owned by insiders or institutions?
Currently 4.49% of Penumbra shares are held by insiders and 82.335% by institutions. How many people work for Penumbra?
Latest data suggests 3,300 work at Penumbra. When does the fiscal year end for Penumbra?
Penumbra's fiscal year ends in December. Where is Penumbra based?
Penumbra's address is: One Penumbra Place, Alameda, CA, United States, 94502 What is Penumbra's ISIN number?
Penumbra's international securities identification number is: US70975L1070 What is Penumbra's CUSIP number?
Penumbra's Committee on Uniform Securities Identification Procedures number is: 70975L107